Nutex Health price target raised to $100 from $75 at Maxim

 Maxim raised the firm’s price target on Nutex Health (NUTX) to $100 from $75 and keeps a Buy rating on the shares. The company delivered significantly better-than-expected Q4 results, driven largely by the company’s success in achieving improved reimbursement by advancing claims through the No Surprises Act’s IDR – independent dispute resolution – process, the analyst tells investors in a research note. Beyond IDR activity, Nutex continues to advance its core growth strategy, with its hospitals expanding service lines to treat higher-acuity patients and to drive increased inpatient and observation visit volumes, the firm adds.

https://www.tipranks.com/news/the-fly/nutex-health-price-target-raised-to-100-from-75-at-maxim